Results 1 to 10 of about 2,353,041 (346)

Machine learning techniques for lipid nanoparticle formulation [PDF]

Nano Convergence
A significant amount of effort has been poured into optimizing the delivery system that is demanded by novel therapeutic modalities. Lipid nanoparticle presents as a solution to transfect cells safely and efficiently with nucleic acid-based therapeutics.
Hao Li, Yayi Zhao, Chenjie Xu
doaj   +3 more sources

mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability

International Journal of Pharmaceutics, 2021
Graphical ...
Linde Schoenmaker, D. Witzigmann, J. Kulkarni, Rein Verbeke, G. Kersten, W. Jiskoot, D. Crommelin   +6 more
semanticscholar   +3 more sources

From Bench to Bedside: Implications of Lipid Nanoparticle Carrier Reactogenicity for Advancing Nucleic Acid Therapeutics

Pharmaceuticals, 2023
In biomedical applications, nanomaterial-based delivery vehicles, such as lipid nanoparticles, have emerged as promising instruments for improving the solubility, stability, and encapsulation of various payloads.
Tetiana Korzun, Abraham S. Moses, Parham Diba, Ariana L. Sattler, Olena R. Taratula, Gaurav Sahay, Oleh Taratula, Daniel L. Marks   +7 more
doaj   +2 more sources

A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems

Nature Communications, 2021
Lipid nanoparticle delivery of mRNA vaccines has become of particular importance, however, mRNA stability is a major concern. Here, the authors report on a study of lipid impurity mRNA interactions using reverse phase ion pair HPLC to identify reactions ...
Meredith Packer, Dipendra Gyawali, Ravikiran Yerabolu, Joseph Schariter, Phil White   +4 more
doaj   +2 more sources

Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine

ACS Nano, 2022
Humans commonly have low level antibodies to poly(ethylene) glycol (PEG) due to environmental exposure. Lipid nanoparticle mRNA vaccines for SARS-CoV-2 contain small amounts of PEG but it is not known if PEG antibodies are enhanced by vaccination and if ...
Yi Ju, W. Lee, Emily H. Pilkington, Hannah G. Kelly, Shiyao Li, K. Selva, Kathleen M. Wragg, K. Subbarao, Thi H. O. Nguyen, L. Rowntree, L. Allen, K. Bond, D. Williamson, N. Truong, M. Plebanski, K. Kedzierska, S. Mahanty, A. Chung, F. Caruso, A. Wheatley, J. Juno, S. Kent   +21 more
semanticscholar   +3 more sources

Lipid-nanoparticle-induced vacuolization in microglia

Communications Biology
Lipid-containing vacuoles in microglia were discovered more than one hundred years ago in the brain of patients showing neurodegenerative processes.
Hubert H. Kerschbaum, Christopher Gerner, Karin Oberascher, Philip Steiner, Melanie Schürz, Nikolaus Bresgen   +5 more
doaj   +4 more sources

Nebulized lipid nanoparticles [PDF]

Nature Reviews Materials, 2021
An article in Nature Biomedical Engineering reports an in vivo workflow for the design of lipid nanoparticles to efficiently deliver mRNA to the lungs via nebulization.
openaire   +2 more sources

Effect of gold nanoparticle on structure and fluidity of lipid membrane. [PDF]

PLoS ONE, 2014
This paper deals with the effect of different size gold nanoparticles on the fluidity of lipid membrane at different regions of the bilayer. To investigate this, we have considered significantly large bilayer leaflets and incorporated only one ...
Anil R Mhashal, Sudip Roy
doaj   +1 more source

Solid Lipid Nanoparticles

Encyclopedia, 2022
Solid lipid nanoparticles (SLNs) are produced from physiologically biocompatible lipids. They have been proven to improve solubility, cellular uptake, and stability, reduce enzyme degradation, and prolong the circulation time of various drugs. SLNs have been applied in the oral, parenteral, transdermal, intranasal, ocular, and pulmonary drug delivery ...
Thi-Thao-Linh Nguyen, Van-An Duong
openaire   +3 more sources

Lipid nanoparticle-encapsulated mRNA therapy corrects serum total bilirubin level in Crigler-Najjar syndrome mouse model

Molecular Therapy: Methods & Clinical Development, 2023
Crigler-Najjar syndrome is a rare disorder of bilirubin metabolism caused by uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) mutations characterized by hyperbilirubinemia and jaundice.
Jenny A. Greig, Joanna K. Chorazeczewski, Vivek Chowdhary, Melanie K. Smith, Matthew Jennis, James C. Tarrant, Elizabeth L. Buza, Kimberly Coughlan, Paolo G.V. Martini, James M. Wilson   +9 more
doaj   +1 more source